<DOC>
	<DOCNO>NCT00820599</DOCNO>
	<brief_summary>A single arm , prospective multicenter non-randomized confirmatory clinical trial evaluate Edwards SAPIEN XT™ transcatheter heart valve ( model 9300TFX ; `` study valve '' ) , transfemoral delivery system , crimper accessory . The trial include premarket confirmatory cohort evaluate system performance well Post Market Clinical Follow-up phase involve expand enrollment long-term follow-up patient evaluate valve performance 5 year .</brief_summary>
	<brief_title>Transfemoral Placement Aortic Balloon Expandable Transcatheter Valves Trial ( Europe )</brief_title>
	<detailed_description>Edwards Lifesciences obtain CE mark authorization transfemoral delivery / implantation Edwards SAPIEN™ transcatheter heart valve ( model 9000TFX ) use RetroFlex™ delivery system August 2007 introduce device commercial distribution European Economic Area ( EEA ) October 2007 . Clinical Sites : Up 11 site Europe</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>All candidate study must meet follow inclusion criterion : 1 . Patients must comorbidities surgeon ( Co Investigator ) interventional cardiologist ( Principal Investigator ) concur predict risk operative mortality &gt; 15 % minimum STS Risk Calculator score ≥ 10 and/or Logistic EuroSCORE &gt; 20 % . 2 . Patient symptomatic his/her aortic valve stenosis , demonstrate NYHA Functional Class II great . 3 . The subject subject 's legal representative inform nature study , agree provision provide write informed consent approve review Ethics Committee ( EC ) respective clinical site . 4 . Subject willing comply specify follow evaluation , include possible coronary angiography transesophageal echocardiography . 5 . The subject treating physician agree subject return require postprocedure followup visit . 1 . Aortic valve congenital unicuspid bicuspid valve , noncalcified . 2 . Mixed aortic valve disease ( aortic stenosis aortic regurgitation predominant aortic regurgitation &gt; 3+ ) . 3 . Any therapeutic invasive cardiac procedure , BAV , perform within 30 day index procedure ( 6 month procedure drug elute coronary stent implantation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sapien Valve</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Heart Valve Therapy</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>Transcatheter</keyword>
</DOC>